Compare JBDI & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JBDI | BMRA |
|---|---|---|
| Founded | 1983 | 1971 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3M | 11.5M |
| IPO Year | 2023 | 1995 |
| Metric | JBDI | BMRA |
|---|---|---|
| Price | $1.00 | $1.84 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.3K | ★ 23.3K |
| Earning Date | 10-15-2026 | 10-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,453,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.39 | $1.45 |
| 52 Week High | $2.11 | $3.21 |
| Indicator | JBDI | BMRA |
|---|---|---|
| Relative Strength Index (RSI) | 41.84 | 35.99 |
| Support Level | $1.00 | $1.50 |
| Resistance Level | $1.47 | $2.26 |
| Average True Range (ATR) | 0.08 | 0.15 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 50.96 | 0.00 |
JBDI Holdings Ltd, through its subsidiaries, is mainly engaged in the reconditioning and recycling of containers in Singapore. Its products include reconditioned and new steel drums, plastic drums, carboys, and IBCs with different capacities, and its customers span various industries such as the solvent, chemical, petroleum, and edible oil industries. Additionally, the Group offers ancillary services, such as reconditioning services, wastewater equipment services, and sales of recycled materials and services to complement its core business. The majority of its revenue is derived from the sale of reconditioned containers. Geographically, the Group derives all its revenue from Singapore.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America generating key revenue from North American Markets.